Brain 17 Vienna

PROFILE trial 1014

ALK+ advanced NSCLC

randomise

crizotinib

cisplat/carbo pemetrexed

172 patients

171 patients

343 patients

Brain metastases in patients with ALK-positive NSCLC

Solomon et al 2016, J Clin Oncol; 34 (24), 2858-65